<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297804</url>
  </required_header>
  <id_info>
    <org_study_id>S2009</org_study_id>
    <secondary_id>TAXUS VI</secondary_id>
    <nct_id>NCT00297804</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions</brief_title>
  <acronym>TAXUS VI</acronym>
  <official_title>TAXUS VI - A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical investigation is an international, prospective, multi-center, double-blind,&#xD;
      randomized safety and efficacy trial. The purpose of this study is to evaluate the safety and&#xD;
      effectiveness of the TAXUS(TM)Stent System with 1µg/mm2 (loaded drug/stent surface area) of&#xD;
      paclitaxel incorporated into a moderate rate-release formulation of triblock copolymer&#xD;
      carrier system in patients with a higher risk of target lesion revascularisation and&#xD;
      restenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ultimate goal of a paclitaxel eluting stent system is to prevent restenosis by blunting&#xD;
      the initial response to stent implant injury and sustaining the arrested response until&#xD;
      vascular healing has taken place.&#xD;
&#xD;
      The purpose of the TAXUS VI trial is to study the safety and efficacy of the TAXUS(TM)Stent&#xD;
      under controlled trial circumstances and targets patients with a higher risk of target lesion&#xD;
      revascularisation and restenosis. The study population will include longer lesions, smaller&#xD;
      diameter vessels, multiple lesions in the same vessel, and allows for the use of up to 2&#xD;
      randomized study stents.&#xD;
&#xD;
      The clinical investigation will evaluate the safety and effectiveness of the TAXUS(TM)Stent&#xD;
      with 1 µg/mm2 (loaded drug/stent surface area) of paclitaxel incorporated into a moderate&#xD;
      rate-release formulation of a triblock copolymer carrier system for treatment of de novo&#xD;
      coronary artery lesions.&#xD;
&#xD;
      Patients are stratified by site and presence or absence of medically treated diabetes&#xD;
      mellitus and then randomized to receive either the TAXUS(TM)Stent or the uncoated&#xD;
      EXPRESS(TM)stent.&#xD;
&#xD;
      The primary objective of the study is to show superior 9-month target vessel&#xD;
      revascularization (TVR) rate for TAXUS(TM) Stent compared to uncoated Express(TM)control&#xD;
      stent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of TVR 9 months after index procedure</measure>
    <time_frame>9 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Rates of composite Major Adverse Cardiac Events (MACE) and the individual components of MACE, assessed at 1, 3, 6 and 9 months after the study procedure and annually for 5 years (i.e., 1, 2, 3, 4, and 5 years after the study procedure).</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate.</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical procedural success.</measure>
    <time_frame>Post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Additional angiographic endpoints at 9 month angiographic follow-up</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS assessment in a subset of approximately 200 patients. At the baseline procedure (post-procedural) and at 9 month follow-up the absolute neointimal volume and the change in neointimal volume from post-procedure to follow-up will be analysed.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">448</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS Express Paclitaxel-Eluting Coronary Stent System</intervention_name>
    <description>Paclitaxel-Eluting Coronary Stent System</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control stent</intervention_name>
    <description>control stent</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General Inclusion Criteria&#xD;
&#xD;
               1. Patient &gt;or= 18 years old&#xD;
&#xD;
               2. Eligible for percutaneous coronary intervention&#xD;
&#xD;
               3. Documented stable angina pectoris or unstable angina pectoris with documented&#xD;
                  ischemia or documented silent ischemia&#xD;
&#xD;
               4. Acceptable candidate for CABG&#xD;
&#xD;
               5. Patient (or legal guardian) understands the study requirements and the treatment&#xD;
                  procedures and provides written Informed Consent before any study-specific tests&#xD;
                  or procedures are performed&#xD;
&#xD;
               6. Willing to comply with all specified follow-up evaluations&#xD;
&#xD;
          -  Angiographic Inclusion Criteria&#xD;
&#xD;
               1. Target lesion located within a single native coronary vessel&#xD;
&#xD;
               2. Target lesion randomized to treatment with the study device may be composed of&#xD;
                  multiple lesions but must be completely coverable by up to 2 study stents&#xD;
                  (maximum allowable stent length of 48 mm).&#xD;
&#xD;
               3. Cumulative target lesion length is &gt;or= 18 mm and &lt;or= 40 mm (visual estimate)&#xD;
&#xD;
               4. RVD of &gt;or= 2.5 mm to &lt;or= 3.75 mm (visual estimate)&#xD;
&#xD;
               5. Target lesion diameter stenosis &gt;or=50% (visual estimate)&#xD;
&#xD;
               6. Target lesion is de novo&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General Exclusion Criteria:&#xD;
&#xD;
               1. Known sensitivity to paclitaxel&#xD;
&#xD;
               2. Any previous or planned treatment with any anti-restenotic drug-coated or&#xD;
                  drug-eluting coronary stent (Note: previous or planned treatment with heparin or&#xD;
                  phosphorylcholine coated stents is acceptable, as long as the procedure with the&#xD;
                  stent meets the protocol defined criteria for staged procedures)&#xD;
&#xD;
               3. Previous or planned treatment with intravascular brachytherapy in the target&#xD;
                  vessel&#xD;
&#xD;
               4. MI within 72 hours prior to the study procedure and/or CK-MB &gt;2x the local&#xD;
                  laboratory's upper limits of normal (refers to a measured value on the day of the&#xD;
                  study procedure)&#xD;
&#xD;
               5. Left ventricular ejection fraction &lt;25%&#xD;
&#xD;
               6. Cerebrovascular Accident within the past 6 months&#xD;
&#xD;
               7. Acute or chronic renal dysfunction (creatinine &gt;1.7 mg/dl or &gt;150 µmol/L)&#xD;
&#xD;
               8. Contraindication to ASA, or to both clopidogrel and ticlopidine&#xD;
&#xD;
               9. Leukopenia (leukocyte count &lt;3.5 x 109/liter)&#xD;
&#xD;
              10. Thrombocytopenia (platelet count &lt;100,000/mm3)&#xD;
&#xD;
              11. Active peptic ulcer or active gastrointestinal bleeding&#xD;
&#xD;
              12. Known allergy to stainless steel&#xD;
&#xD;
              13. Any prior true anaphylactic reaction to contrast agents&#xD;
&#xD;
              14. Known anaphylactoid or other non-anaphylactic allergic reactions to contrast&#xD;
                  agents that cannot be adequately pre-medicated prior to the study procedure&#xD;
&#xD;
              15. Patient is currently taking colchicine&#xD;
&#xD;
              16. Patient is currently, or has been treated with paclitaxel within 12 months of the&#xD;
                  study procedure&#xD;
&#xD;
              17. Female of childbearing potential with a positive pregnancy test within 7 days&#xD;
                  before the study procedure, or lactating, or intends to become pregnant during&#xD;
                  the study&#xD;
&#xD;
              18. Life expectancy of less than 24 months due to other medical conditions&#xD;
&#xD;
              19. Co-morbid condition(s) that could limit the patient's ability to participate in&#xD;
                  the study, compliance with follow-up requirements or impact the scientific&#xD;
                  integrity of the study&#xD;
&#xD;
              20. Currently participating in another investigational drug or device study that has&#xD;
                  not completed the primary endpoint or that clinically interferes with the&#xD;
                  endpoints of this study&#xD;
&#xD;
          -  Angiographic Exclusion Criteria&#xD;
&#xD;
               1. Left main coronary artery disease (stenosis &gt;50%), whether protected or&#xD;
                  unprotected&#xD;
&#xD;
               2. Target lesion is ostial in location (within 3.0 mm of vessel origin)&#xD;
&#xD;
               3. Target lesion(s) and/or target vessel proximal to the target lesion(s) is&#xD;
                  moderately or severely calcified by visual estimation&#xD;
&#xD;
               4. Target lesion is located within or distal to a &gt;60°bend in the vessel&#xD;
&#xD;
               5. Target lesion involves a bifurcation with a diseased (&gt;50% stenotic) branch&#xD;
                  vessel &gt;2.0 mm in diameter&#xD;
&#xD;
               6. Target lesion is totally occluded Thrombolysis in MI (TIMI flow &lt;or= 1)&#xD;
&#xD;
               7. Angiographic presence of probable or definite thrombus&#xD;
&#xD;
               8. Target vessel will be pre-treated with an unapproved device, directional or&#xD;
                  rotational coronary atherectomy, laser, cutting balloon or transluminal&#xD;
                  extraction catheter immediately prior to stent placement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eberhard Grube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HELIOS Clinic Siegburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HELIOS Clinic</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>February 27, 2006</study_first_submitted>
  <study_first_submitted_qc>February 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2006</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <name_title>Thomas Naeschen</name_title>
    <organization>Boston Scientific</organization>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Stent Implant</keyword>
  <keyword>Drug-coated Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

